Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 14/02/2019, Revision: 13, Status

Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 14/02/2019, Revision: 13, Status: Authorised